Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2019

• Venue

  American Journal of Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 30755814PMCID PMC6356924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The post-translational modification, SUMOylation, and cancer (Review)

  2018cited by this paper
• SUMO and the robustness of cancer

  2017cited by this paper
• C-terminal motifs in promyelocytic leukemia protein isoforms critically regulate PML nuclear body formation

  2017cited by this paper
• Protein SUMOylation modification and its associations with disease

  2017cited by this paper
• The DNA damage-induced cell death response: a roadmap to kill cancer cells

  2016cited by this paper
• Homeodomain-Interacting Protein Kinase-2: A Critical Regulator of the DNA Damage Response and the Epigenome

  2016cited by this paper
• Structural and functional characterization of the phosphorylation-dependent interaction between PML and SUMO1.

  2015cited by this paper
• HIPK2 modification code for cell death and survival

  2014cited by this paper
• HIPK2: A tumour suppressor that controls DNA damage‐induced cell fate and cytokinesis

  2013cited by this paper
• Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death

  2013cited by this paper
• Post-translational modifications of PML: consequences and implications

  2013cited by this paper
• WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation.

  2013cited by this paper
• Differential Roles of PML Isoforms

  2013cited by this paper
• Posttranslational modifications regulate HIPK2, a driver of proliferative diseases

  2013cited by this paper
• A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress.

  2012cited by this paper
• Control of nuclear HIPK2 localization and function by a SUMO interaction motif.

  2011cited by this paper
• Deregulated transcription factors in leukemia

  2011cited by this paper
• Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.

  2011cited by this paper
• A Role for Non-Covalent SUMO Interaction Motifs in Pc2/CBX4 E3 Activity

  2010cited by this paper
• Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells

  2010cited by this paper
• Assembly dynamics of PML nuclear bodies in living cells

  2010cited by this paper
• Small Ubiquitin-related Modifier (SUMO) Binding Determines Substrate Recognition and Paralog-selective SUMO Modification*

  2008cited by this paper
• Dynamics of component exchange at PML nuclear bodies

  2008cited by this paper
• Ubiquitination and Degradation of Homeodomain-interacting Protein Kinase 2 by WD40 Repeat/SOCS Box Protein WSB-1*

  2008cited by this paper
• PML Activates Transcription by Protecting HIPK2 and p300 from SCFFbx3-Mediated Degradation

  2008cited by this paper
• Structure of the Small Ubiquitin-like Modifier (SUMO)-interacting Motif of MBD1-containing Chromatin-associated Factor 1 Bound to SUMO-3*

  2008cited by this paper
• Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription

  2007cited by this paper
• Specification of SUMO1- and SUMO2-interacting Motifs*

  2006cited by this paper
• Roles of HIPK1 and HIPK2 in AML1‐ and p300‐dependent transcription, hematopoiesis and blood vessel formation

  2006cited by this paper
• Small Ubiquitin-like Modifier (SUMO) Recognition of a SUMO Binding Motif

  2005cited by this paper
• Differential interactions of the homeodomain‐interacting protein kinase 2 (HIPK2) by phosphorylation‐dependent sumoylation

  2005cited by this paper
• Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability.

  2005cited by this paper
• Regulation of Homeodomain-interacting Protein Kinase 2 (HIPK2) Effector Function through Dynamic Small Ubiquitin-related Modifier-1 (SUMO-1) Modification*

  2005cited by this paper
• Physical and functional link of the leukemia-associated factors AML1 and PML.

  2005cited by this paper
• Identification of a SUMO-binding motif that recognizes SUMO-modified proteins.

  2004cited by this paper
• SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?

  2004cited by this paper
• The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.

  2003cited by this paper
• Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis

  2002cited by this paper
• Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2

  2002cited by this paper
• The Small Ubiquitin-like Modifier-1 (SUMO-1) Consensus Sequence Mediates Ubc9 Binding and Is Essential for SUMO-1 Modification*

  2001cited by this paper
• Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif.

  2000cited by this paper
• Characterization of a Novel Serine/Threonine Kinase Associated with Nuclear Bodies*

  2000cited by this paper
• Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1.

  1999cited by this paper
• Activation of androgen receptor function by a novel nuclear protein kinase.

  1998cited by this paper
• Structure determination of the small ubiquitin-related modifier SUMO-1.

  1998cited by this paper
• Homeodomain-interacting Protein Kinases, a Novel Family of Co-repressors for Homeodomain Transcription Factors*

  1998cited by this paper
• Oncogenic transcription factors in the human acute leukemias.

  1997cited by this paper
• Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia.

  1992cited by this paper
• Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group

  1976cited by this paper

• Biology and pharmacological inhibition of homeodomain-interacting protein kinases

  2025cites this paper
• The role of SUMOylation in biomolecular condensate dynamics and protein localization

  2024cites this paper
• The Sweet Side of HIPK2

  2023cites this paper
• Acute Myeloid Leukemia-Related Proteins Modified by Ubiquitin and Ubiquitin-like Proteins

  2022cites this paper
• HIPK2 in cancer biology and therapy: Recent findings and future perspectives.

  2022cites this paper
• DAZAP2 acts as specifier of the p53 response to DNA damage

  2021cites this paper
• The important roles of protein SUMOylation in the occurrence and development of leukemia and clinical implications

  2020cites this paper
• SUMOylation homeostasis in tumorigenesis.

  2019cites this paper
• The SUMO Pathway in Hematomalignancies and Their Response to Therapies

  2019cites this paper